Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | RARB | P10826 | 3/20 | 0.62 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.61 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382628 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5814527 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5820211 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5819932 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL382171 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4798961 | 1.00 | TP53 (0.68) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4365542 | 0.95 | LTA4H (0.63) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL4366629 | 0.95 | LTA4H (0.63) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5816099 | 0.94 | TP53 (0.60) | TP53TSHRPLA2G4BLTA4HRARB | |
| SCHEMBL5819940 | 0.94 | TP53 (0.60) | TP53TSHRPLA2G4BLTA4HRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345163-B2 | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2008-03-18 | — | — | US | claimed |
| WO-2006132588-A1 | METHOD FOR THE PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES CONTAINING ONE OR SEVERAL LABELS | QUIATECH AB (SE) | 2006-12-14 | — | — | WO | claimed |
| CN-1678618-A | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2005-10-05 | — | — | CN | claimed |
| EP-1546166-A1 | PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES | Quiatech AB (SE) | 2005-06-29 | — | — | EP | claimed |
| WO-2004020449-A1 | PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES | QUIATECH AB (SE) | 2004-03-11 | — | — | WO | claimed |
| US-20040044195-A1 | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2004-03-04 | — | — | US | claimed |
| US-7345163-B2 | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2008-03-18 | — | — | US | disclosed |
| WO-2006132588-A1 | METHOD FOR THE PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES CONTAINING ONE OR SEVERAL LABELS | QUIATECH AB (SE) | 2006-12-14 | — | — | WO | disclosed |
| CN-1678618-A | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1546166-A1 | PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES | Quiatech AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004020449-A1 | PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES | QUIATECH AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| US-20040044195-A1 | Process for separating and deprotecting oligonucleotides | QUIATECH AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044195-A1 | Process for separating and deprotecting oligonucleotides | RNGTT, NSUN2, DCLRE1B | TP53 2718/4885TSHR 1891/4885PLA2G4B 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.